ApoE Mimetic Peptide COG1410 Exhibits Strong Additive Interaction with Antibiotics Against Mycobacterium smegmatis

References

• Gygli SM, Borrell S, Trauner A, Gagneux S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol Rev. 2017;41(3):354–373. doi:10.1093/femsre/fux011
   PubMed Web of Science ®Google Scholar
• Allué-Guardia A, García JI, Torrelles JB. Evolution of drug-resistant mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol. 2021;12:612675. doi:10.3389/fmicb.2021.612675
   PubMedGoogle Scholar
• World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO; 2021.
   Google Scholar
• Tadolini M, Garcia-Prats AJ, D’Ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J. 2016;48(3):938–943. doi:10.1183/13993003.00705-2016
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Rhee KY. Tuberculosis drug development: history and evolution of the mechanism-based paradigm. Cold Spring Harb Perspect Med. 2015;5(8):a021147. doi:10.1101/cshperspect.a021147
   PubMed Web of Science ®Google Scholar
• Bardan A, Nizet V, Gallo RL. Antimicrobial peptides and the skin. Expert Opin Biol Ther. 2004;4(4):543–549. doi:10.1517/14712598.4.4.543
   PubMed Web of Science ®Google Scholar
• Nakatsuji T, Gallo RL. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol. 2012;132(3 Pt 2):887–895. doi:10.1038/jid.2011.387
   PubMed Web of Science ®Google Scholar
• Tomasinsig L, Zanetti M. The cathelicidins--structure, function and evolution. Curr Protein Pept Sci. 2005;6(1):23–34. doi:10.2174/1389203053027520
   PubMed Web of Science ®Google Scholar
• AlMatar M, Makky EA, Yakıcı G, Var I, Kayar B, Köksal F. Antimicrobial peptides as an alternative to anti-tuberculosis drugs. Pharmacol Res. 2018;128:288–305. doi:10.1016/j.phrs.2017.10.011
   PubMed Web of Science ®Google Scholar
• Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408–1425. doi:10.1016/j.bbamem.2006.03.030
   PubMed Web of Science ®Google Scholar
• Deshpande D, Grieshober M, Wondany F, et al. Super-resolution microscopy reveals a direct interaction of intracellular mycobacterium tuberculosis with the antimicrobial peptide LL-37. Int J Mol Sci. 2020;21(18):6741. doi:10.3390/ijms21186741
   PubMedGoogle Scholar
• Peláez Coyotl EA, Barrios Palacios J, Muciño G, et al. Antimicrobial peptide against mycobacterium tuberculosis that activates autophagy is an effective treatment for tuberculosis. Pharmaceutics. 2020;12(11):1071. doi:10.3390/pharmaceutics12111071
   PubMed Web of Science ®Google Scholar
• Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30(3):131–141. doi:10.1016/j.it.2008.12.003
   PubMed Web of Science ®Google Scholar
• Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J Biol Chem. 1987;262(29):14352–14360. doi:10.1016/S0021-9258(18)47945-8
   PubMed Web of Science ®Google Scholar
• Zanfardino A, Bosso A, Gallo G, et al. Human apolipoprotein E as a reservoir of cryptic bioactive peptides: the case of ApoE 133–167. J Peptide Sci. 2018;24(7):e3095. doi:10.1002/psc.3095
   PubMed Web of Science ®Google Scholar
• Wang CQ, Yang CS, Yang Y, Pan F, He LY, Wang AM. An apolipoprotein E mimetic peptide with activities against multidrug-resistant bacteria and immunomodulatory effects. J Peptide Sci. 2013;19(12):745–750. doi:10.1002/psc.2570
   PubMed Web of Science ®Google Scholar
• Pane K, Sgambati V, Zanfardino A, et al. A new cryptic cationic antimicrobial peptide from human apolipoprotein E with antibacterial activity and immunomodulatory effects on human cells. FEBS J. 2016;283(11):2115–2131. doi:10.1111/febs.13725
   PubMed Web of Science ®Google Scholar
• Puthia M, Marzinek JK, Petruk G, Ertürk Bergdahl G, Bond PJ, Petrlova J. Antibacterial and anti-inflammatory effects of apolipoprotein E. Biomedicines. 2022;10(6). doi:10.3390/biomedicines10061430
   PubMed Web of Science ®Google Scholar
• Petruk G, Elvén M, Hartman E, et al. The role of full-length apoE in clearance of Gram-negative bacteria and their endotoxins. J Lipid Res. 2021;62:100086. doi:10.1016/j.jlr.2021.100086
   PubMed Web of Science ®Google Scholar
• Chiu LS, Anderton RS, Cross JL, et al. Assessment of R18, COG1410, and APP96-110 in excitotoxicity and traumatic brain injury. Transl Neurosci. 2017;8:147–157. doi:10.1515/tnsci-2017-0021
   PubMed Web of Science ®Google Scholar
• Cao F, Jiang Y, Wu Y, et al. Apolipoprotein E-mimetic COG1410 reduces acute vasogenic edema following traumatic brain injury. J Neurotrauma. 2016;33(2):175–182. doi:10.1089/neu.2015.3887
   PubMed Web of Science ®Google Scholar
• Wang B, Zhang FW, Wang WX, et al. Apolipoprotein E mimetic peptide COG1410 combats pandrug-resistant Acinetobacter baumannii. Front Microbiol. 2022;13:934765. doi:10.3389/fmicb.2022.934765
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, McKenna SE, Song P, et al. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma. 2007;24(7):1093–1107. doi:10.1089/neu.2006.0192
   PubMed Web of Science ®Google Scholar
• Cruz J, Flórez J, Torres R, et al. Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly(lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157:H7 and methicillin resistant Staphylococcus aureus (MRSA). Nanotechnology. 2017;28(13):135102. doi:10.1088/1361-6528/aa5f63
   PubMed Web of Science ®Google Scholar
• Nur Ain Mohd A, Nur Izzati R, Fatin Amira A, et al. Immunomodulation of murine macrophages RAW264.7 infected with mycobacterium smegmatis. Asian J Med Biomed. 2020;4(SI1):40–46.
   Google Scholar
• Gupta K, Singh S, van Hoek ML. Short, synthetic cationic peptides have antibacterial activity against Mycobacterium smegmatis by forming pores in membrane and synergizing with antibiotics. Antibiotics. 2015;4(3):358–378. doi:10.3390/antibiotics4030358
   Google Scholar
• Esteban J, García-Coca M. Mycobacterium Biofilms. Front Microbiol. 2018;8. doi:10.3389/fmicb.2017.02651
   PubMed Web of Science ®Google Scholar
• Bhat KH, Yaseen I. Mycobacterium tuberculosis: macrophage takeover and modulation of innate effector responses. In: Mycobacterium-Research and Development. IntechOpen; 2018.
   Google Scholar
• Zhu C, Liu Y, Hu L, Yang M, He Z-G. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis. J Biol Chem. 2018;293(43):16741–16750. doi:10.1074/jbc.RA118.002693
   PubMed Web of Science ®Google Scholar
• Anuchin AM, Mulyukin AL, Suzina NE, Duda VI, El-Registan GI, Kaprelyants AS. Dormant forms of Mycobacterium smegmatis with distinct morphology. Microbiology. 2009;155(Pt 4):1071–1079. doi:10.1099/mic.0.023028-0
   PubMedGoogle Scholar
• Yagi A, Uchida R, Hamamoto H, Sekimizu K, Kimura K-I, Tomoda H. Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis. J Antibiot. 2017;70(5):685–690. doi:10.1038/ja.2017.23
   PubMed Web of Science ®Google Scholar
• Ramón-García S, Mikut R, Ng C, et al. Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother. 2013;57(5):2295–2303. doi:10.1128/AAC.00175-13
   PubMed Web of Science ®Google Scholar
• Yamada H, Chikamatsu K, Aono A, et al. Smegmatis be used as a real alternative for M. tuberculosis? Eur Respir J. 2016;48(suppl 60):PA2789.
   Google Scholar
• Kartmann B, Stengler S, Niederweis M. Porins in the cell wall of Mycobacterium tuberculosis. J Bacteriol. 1999;181(20):6543–6546. doi:10.1128/JB.181.20.6543-6546.1999
   PubMed Web of Science ®Google Scholar
• Jas T, J R, Rajan A, Shankar V. J R, Rajan A, Shankar V. Features of the biochemistry of Mycobacterium smegmatis, as a possible model for Mycobacterium tuberculosis. J Infect Public Health. 2020;13(9):1255–1264. doi:10.1016/j.jiph.2020.06.023
   PubMed Web of Science ®Google Scholar
• Duong L, Gross SP, Siryaporn A. Developing Antimicrobial Synergy With AMPs. Front Med Technol. 2021;3:640981. doi:10.3389/fmedt.2021.640981
   PubMedGoogle Scholar
• Wu CL, Hsueh JY, Yip BS, Chih YH, Peng KL, Cheng JW. Antimicrobial peptides display strong synergy with vancomycin against vancomycin-resistant E. faecium, S. aureus, and wild-type E. coli. Int J Mol Sci. 2020;21(13):4578.
   PubMed Web of Science ®Google Scholar
• Abedinzadeh M, Gaeini M, Sardari S. Natural antimicrobial peptides against Mycobacterium tuberculosis. J Antimicrob Chemother. 2015;70(5):1285–1289. doi:10.1093/jac/dku570
   PubMed Web of Science ®Google Scholar
• Aguilar-Pérez C, Gracia B, Rodrigues L, et al. Synergy between circular bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;62(9):e00359–00318. doi:10.1128/AAC.00359-18
   PubMed Web of Science ®Google Scholar
• Sharma A, Gaur A, Kumar V, et al. Antimicrobial activity of synthetic antimicrobial peptides loaded in poly-Ɛ-caprolactone nanoparticles against mycobacteria and their functional synergy with rifampicin. Int J Pharm. 2021;608:121097. doi:10.1016/j.ijpharm.2021.121097
   PubMedGoogle Scholar
• Rao KU, Henderson DI, Krishnan N, et al. A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy. Sci Rep. 2021;11(1):4201. doi:10.1038/s41598-021-83755-3
   PubMed Web of Science ®Google Scholar
• Usmani SS, Kumar R, Kumar V, Singh S, Raghava GPS. AntiTbPdb: a knowledgebase of anti-tubercular peptides. Database. 2018;2018. doi:10.1093/database/bay025
   PubMedGoogle Scholar
• Oliveira GS, Costa RP, Gomes P, Gomes MS, Silva T, Teixeira C. Antimicrobial peptides as potential anti-tubercular leads: a concise review. Pharmaceuticals. 2021;14(4):323. doi:10.3390/ph14040323
   Web of Science ®Google Scholar
• Carroll J, Field D, O’Connor PM, et al. Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioeng Bugs. 2010;1(6):408–412. doi:10.4161/bbug.1.6.13642
   PubMedGoogle Scholar